JP2024156878A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024156878A5 JP2024156878A5 JP2024127876A JP2024127876A JP2024156878A5 JP 2024156878 A5 JP2024156878 A5 JP 2024156878A5 JP 2024127876 A JP2024127876 A JP 2024127876A JP 2024127876 A JP2024127876 A JP 2024127876A JP 2024156878 A5 JP2024156878 A5 JP 2024156878A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- abc
- klrg1
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012634 fragment Substances 0.000 claims description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 7
- 239000000427 antigen Substances 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 description 11
- 150000007523 nucleic acids Chemical class 0.000 description 11
- 102000039446 nucleic acids Human genes 0.000 description 11
- 101000971533 Homo sapiens Killer cell lectin-like receptor subfamily G member 1 Proteins 0.000 description 10
- 102100021457 Killer cell lectin-like receptor subfamily G member 1 Human genes 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 102000000905 Cadherin Human genes 0.000 description 6
- 108050007957 Cadherin Proteins 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 241000282567 Macaca fascicularis Species 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 230000006051 NK cell activation Effects 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862732329P | 2018-09-17 | 2018-09-17 | |
| US62/732,329 | 2018-09-17 | ||
| PCT/US2019/050110 WO2020060781A1 (en) | 2018-09-17 | 2019-09-06 | Anti-klrg1 antibodies |
| JP2021539334A JP7654548B2 (ja) | 2018-09-17 | 2019-09-06 | 抗ｋｌｒｇ１抗体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021539334A Division JP7654548B2 (ja) | 2018-09-17 | 2019-09-06 | 抗ｋｌｒｇ１抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024156878A JP2024156878A (ja) | 2024-11-06 |
| JP2024156878A5 true JP2024156878A5 (https=) | 2025-01-29 |
Family
ID=69887899
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021539334A Active JP7654548B2 (ja) | 2018-09-17 | 2019-09-06 | 抗ｋｌｒｇ１抗体 |
| JP2024127876A Pending JP2024156878A (ja) | 2018-09-17 | 2024-08-02 | 抗ｋｌｒｇ１抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021539334A Active JP7654548B2 (ja) | 2018-09-17 | 2019-09-06 | 抗ｋｌｒｇ１抗体 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12365735B2 (https=) |
| EP (1) | EP3852779A4 (https=) |
| JP (2) | JP7654548B2 (https=) |
| KR (1) | KR102934267B1 (https=) |
| CN (2) | CN119638835A (https=) |
| AU (1) | AU2019344524A1 (https=) |
| BR (1) | BR112021004553A2 (https=) |
| CA (1) | CA3113069A1 (https=) |
| EA (1) | EA202190647A1 (https=) |
| IL (2) | IL281594B2 (https=) |
| MX (2) | MX2021003119A (https=) |
| SG (1) | SG11202102114UA (https=) |
| WO (1) | WO2020060781A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020060781A1 (en) | 2018-09-17 | 2020-03-26 | Abcuro, Inc. | Anti-klrg1 antibodies |
| WO2022056289A1 (en) * | 2020-09-11 | 2022-03-17 | National Jewish Health | Methods and compositions for treating respiratory diseases or conditions related to innate lymphoid cells |
| AU2022246164A1 (en) * | 2021-03-26 | 2023-09-28 | The Brigham And Women’S Hospital, Inc. | Anti-klrg1 antibodies |
| WO2022204529A1 (en) | 2021-03-26 | 2022-09-29 | Abcuro, Inc. | Anti-klrg1 antibodies |
| WO2024072872A2 (en) * | 2022-09-27 | 2024-04-04 | The Brigham And Women's Hospital, Inc. | Klrg1 signalling therapy for infectious disease |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
| EP1810035A4 (en) | 2004-11-10 | 2010-03-17 | Macrogenics Inc | GENERATION OF FC ANTIBODY REGIONS FOR EFFECTOR FUNCTION |
| DK1817340T3 (da) | 2004-11-12 | 2012-08-13 | Xencor Inc | Fc-varianter med ændret binding til fcrn |
| WO2006076594A2 (en) | 2005-01-12 | 2006-07-20 | Xencor, Inc. | Antibodies and fc fusion proteins with altered immunogenicity |
| CN103536915A (zh) | 2006-12-27 | 2014-01-29 | 埃默里大学 | 用于治疗传染病和肿瘤的组合物和方法 |
| HRP20160855T1 (hr) | 2008-02-08 | 2016-09-23 | Medimmune, Llc | Anti-ifnar1 protutijela sa smanjenim afinitetom fc liganda |
| ES2624835T3 (es) * | 2009-08-06 | 2017-07-17 | Immunas Pharma, Inc. | Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos |
| US10053513B2 (en) | 2009-11-30 | 2018-08-21 | Janssen Biotech, Inc. | Antibody Fc mutants with ablated effector functions |
| AU2011295902B2 (en) | 2010-09-02 | 2014-12-04 | Vaccinex, Inc. | Anti-CXCL13 antibodies and methods of using the same |
| SG10201602394QA (en) | 2011-03-29 | 2016-05-30 | Roche Glycart Ag | Antibody FC Variants |
| WO2012145746A1 (en) | 2011-04-21 | 2012-10-26 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for the treatment of neuromyelitis optica |
| PL2718322T3 (pl) | 2011-06-06 | 2019-07-31 | Novo Nordisk A/S | Lecznicze przeciwciała |
| WO2012176765A1 (ja) | 2011-06-24 | 2012-12-27 | 株式会社ペルセウスプロテオミクス | 抗ヒトｐ－カドへリン（ｃｄｈ３）遺伝子組み換え抗体 |
| RU2687043C2 (ru) | 2013-04-29 | 2019-05-06 | Ф. Хоффманн-Ля Рош Аг | МОДИФИЦИРОВАННЫЕ АСИММЕТРИЧНЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Fc-РЕЦЕПТОР, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| EP3119424A4 (en) | 2014-03-19 | 2017-09-13 | MacKay Medical Foundation the Presbyterian Church in Taiwan MacKay Memorial Hospital | Immunogenic glycopeptides, composition comprising the glycopeptides and use thereof |
| WO2016009487A1 (ja) | 2014-07-14 | 2016-01-21 | 三菱電機株式会社 | 空気調和装置 |
| WO2017019846A1 (en) | 2015-07-30 | 2017-02-02 | Macrogenics, Inc. | Pd-1-binding molecules and methods use thereof |
| EP3352760B1 (en) | 2015-09-21 | 2026-03-11 | Aptevo Research and Development LLC | Cd3 binding polypeptides |
| WO2017060144A1 (en) | 2015-10-07 | 2017-04-13 | F. Hoffmann-La Roche Ag | Bispecific antibodies with tetravalency for a costimulatory tnf receptor |
| KR102799807B1 (ko) | 2015-12-30 | 2025-04-24 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| WO2017152102A2 (en) | 2016-03-04 | 2017-09-08 | Alector Llc | Anti-trem1 antibodies and methods of use thereof |
| WO2017210523A1 (en) * | 2016-06-03 | 2017-12-07 | The Brigham And Women's Hospital | Klrg1 signaling therapy |
| AU2017326003A1 (en) * | 2016-09-16 | 2019-04-11 | Children's Medical Center Corporation | KLRG1 depletion therapy |
| WO2018140831A2 (en) | 2017-01-27 | 2018-08-02 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| CA3059938A1 (en) | 2017-04-14 | 2018-10-18 | Kodiak Sciences Inc. | Complement factor d antagonist antibodies and conjugates thereof |
| US20180371088A1 (en) | 2017-06-22 | 2018-12-27 | Development Center For Biotechnology | TARGET CELL-DEPENDENT T CELL ENGAGING AND ACTIVATION ASYMMETRIC HETERODIMERIC Fc-ScFv FUSION ANTIBODY FORMAT AND USES THEREOF IN CANCER THERAPY |
| US20210002373A1 (en) | 2018-03-01 | 2021-01-07 | Nextcure, Inc. | KLRG1 Binding Compositions and Methods of Use Thereof |
| WO2020060781A1 (en) | 2018-09-17 | 2020-03-26 | Abcuro, Inc. | Anti-klrg1 antibodies |
| EP3952999A4 (en) | 2019-04-09 | 2023-01-25 | Abcuro, Inc. | Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies |
| AU2022246164A1 (en) | 2021-03-26 | 2023-09-28 | The Brigham And Women’S Hospital, Inc. | Anti-klrg1 antibodies |
-
2019
- 2019-09-06 WO PCT/US2019/050110 patent/WO2020060781A1/en not_active Ceased
- 2019-09-06 IL IL281594A patent/IL281594B2/en unknown
- 2019-09-06 CN CN202411978380.6A patent/CN119638835A/zh active Pending
- 2019-09-06 BR BR112021004553-8A patent/BR112021004553A2/pt unknown
- 2019-09-06 JP JP2021539334A patent/JP7654548B2/ja active Active
- 2019-09-06 SG SG11202102114UA patent/SG11202102114UA/en unknown
- 2019-09-06 US US17/285,793 patent/US12365735B2/en active Active
- 2019-09-06 MX MX2021003119A patent/MX2021003119A/es unknown
- 2019-09-06 KR KR1020217008068A patent/KR102934267B1/ko active Active
- 2019-09-06 CA CA3113069A patent/CA3113069A1/en active Pending
- 2019-09-06 EA EA202190647A patent/EA202190647A1/ru unknown
- 2019-09-06 AU AU2019344524A patent/AU2019344524A1/en active Pending
- 2019-09-06 CN CN201980060735.4A patent/CN112752580B/zh active Active
- 2019-09-06 EP EP19862063.5A patent/EP3852779A4/en active Pending
-
2021
- 2021-03-16 MX MX2025008993A patent/MX2025008993A/es unknown
-
2024
- 2024-08-02 JP JP2024127876A patent/JP2024156878A/ja active Pending
-
2025
- 2025-09-04 IL IL323170A patent/IL323170A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024156878A5 (https=) | ||
| JP2025065142A5 (https=) | ||
| US12024559B2 (en) | Fusions with CD8 antigen binding molecules for modulating immune cell function | |
| JP6526189B2 (ja) | 抗ｐｄ−ｌ１抗体並びにその治療及び診断のための使用 | |
| JP2024150751A5 (https=) | ||
| CN110035773B (zh) | 新型抗ctla4抗体 | |
| CA3142738A1 (en) | Fusions of mutant interleukin-2 polypeptides with antigen binding molecules for modulating immune cell function | |
| JP2018533371A5 (https=) | ||
| JP2020010699A5 (https=) | ||
| CA3086653A1 (en) | Tumor necrosis factor (tnf) receptor superfamily (tnfrsf) receptor-activating antibody fusion proteins with fcyr-independent agonistic activity (tnfrsf receptor-activating antibody fusion proteins with fcyr-independ ent agonistic activity; traaffiaa) | |
| JPWO2019152742A5 (https=) | ||
| KR20170012347A (ko) | 삼중-특이적 결합 분자 및 그것의 사용 방법 | |
| TW201632559A (zh) | 結合ｃｄ１３７之抗體治療劑 | |
| JP2026050358A (ja) | 治療用抗ｃｄ４０リガンド抗体 | |
| JP2017184753A (ja) | ＩＬ７受容体のα鎖に対する抗体‐薬剤候補物質の製造におけるこれらの使用 | |
| TW201730212A (zh) | Ｒｏｒ１－結合分子及其使用方法 | |
| KR20110103431A (ko) | 미오스타틴 결합 단백질 | |
| JP2022501065A5 (https=) | ||
| TWI814715B (zh) | Ａｄａｍ９結合分子及使用其的方法 | |
| RU2006111579A (ru) | Антитела к рецептору интерлейкина-1 и их применение | |
| JP2019524100A5 (https=) | ||
| CN116390953A (zh) | 靶向人密蛋白18.2的抗体及其用途 | |
| JP7712925B2 (ja) | 腫瘍治療のための二重特異性融合タンパク質と抗Ｈｅｒ２抗体の組合せ | |
| CN115175941A (zh) | 微型制导和导航控制(miniGNC)抗体样蛋白及其制备和使用方法 | |
| WO2022125712A1 (en) | Fusions of mutant interleukin-10 polypeptides with antigen binding molecules for modulating immune cell function |